Nooshin Ahmadirad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Nooshin Ahmadirad has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
Mohammad Taghi Joghataei
Cellular and Molecular Research Center (CMRC), Iran University of Medical Sciences (IUMS), Shahid Hemmat Highway, Tehran, 14496-14535, Iran
6 shared publicationsSam Zarbakhsh
Nervous System Stem Cells Research Center, Semnan University of Medical Sciences, Semnan, Iran
4 shared publicationsSamaneh Dehghan
Stem Cell and Regenerative Medicine Research Center, Iran University of Medical Sciences, Tehran, Iran
4 shared publicationsFaeze Sadat Ahmadi Tabatabaei
Cellular and Molecular Research Center (CMRC), Iran University of Medical Sciences (IUMS), Shahid Hemmat Highway, Tehran, 14496-14535, Iran
3 shared publicationsFereshteh Golab
Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran
3 shared publications- Fariba Karimzadeh
Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran
2 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by InkVista Publishing House in North Khorasan University of Medical Sciences
- Vol. 18 (2) , 12-25
Applications of Mesenchymal Stem Cells in Spinal Cord Injury Repair: A Review of Advances, Mechanisms, and Recent Clinical Studies
Introduction: Spinal cord injury (SCI) is a traumatic condition that causes sensory and motor deficits, affecting more than one million people worldwide. Current pharmacological treatments can only reduce injury severity and prevent further damage to the central nervous system, but none have succeeded in promoting axonal regeneration. In recent years, cell ...
- 1 July 2026
- Published by InkVista Publishing House in North Khorasan University of Medical Sciences
- Vol. 18 (2) , 12-25
Open AccessApplications of Mesenchymal Stem Cells in Spinal Cord Injury Repair: A Review of Advances, Mechanisms, and Recent Clinical Studies
Introduction: Spinal cord injury (SCI) is a traumatic condition that causes sensory and motor deficits, affecting more than one million people worldwide. Current pharmacological treatments can only reduce injury severity and prevent further damage to the central nervous system, but none have succeeded in promoting axonal regeneration. In recent years, cell ...
- Open Access
- 2 February 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (2) , 215
Correction to: Bioelectric Modulation in Epilepsy: A Comparative Review of High-Frequency Stimulation and Low-Frequency Stimulation
- 2 February 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (2) , 215
Open AccessCorrection to: Bioelectric Modulation in Epilepsy: A Comparative Review of High-Frequency Stimulation and Low-Frequency Stimulation
- 8 October 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (12) , 6445-6456
Bioelectric Modulation in Epilepsy: A Comparative Review of High-Frequency Stimulation and Low-Frequency Stimulation
Drug-resistant epilepsy affects a significant portion of epileptic patients, necessitating alternative treatment strategies beyond pharmacological interventions. Bioelectric medicine, employing techniques like vagus nerve stimulation, deep brain stimulation, and responsive neurostimulation, has emerged as a promising approach. This review comparatively analyzes the mechanisms and clinical outcomes of high-frequency stimulation and low-frequency stimulation in the context of epilepsy treatment. We delve into the synaptic plasticity, neuronal network modulation, and neurochemical alterations induced by these stimulation paradigms, highlighting their potential to disrupt pathological synchronization and reduce seizure frequency. Furthermore, we discuss the rationale for selecting specific stimulation frequencies and target brain regions, considering the heterogeneity of epilepsy syndromes. By synthesizing existing literature, this review aims to provide a comprehensive overview of bioelectric approaches in epilepsy, informing future research and clinical applications.
- 8 October 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (12) , 6445-6456
Bioelectric Modulation in Epilepsy: A Comparative Review of High-Frequency Stimulation and Low-Frequency Stimulation
Drug-resistant epilepsy affects a significant portion of epileptic patients, necessitating alternative treatment strategies beyond pharmacological interventions. Bioelectric medicine, employing techniques like vagus nerve stimulation, deep brain stimulation, and responsive neurostimulation, has emerged as a promising approach. This review comparatively analyzes the mechanisms and clinical outcomes of high-frequency stimulation and low-frequency stimulation in the context of epilepsy treatment. We delve into the synaptic plasticity, neuronal network modulation, and neurochemical alterations induced by these stimulation paradigms, highlighting their potential to disrupt pathological synchronization and reduce seizure frequency. Furthermore, we discuss the rationale for selecting specific stimulation frequencies and target brain regions, considering the heterogeneity of epilepsy syndromes. By synthesizing existing literature, this review aims to provide a comprehensive overview of bioelectric approaches in epilepsy, informing future research and clinical applications.
- Open Access
- 5 August 2025
- Published by Elsevier in Interdisciplinary Neurosurgery
- Vol. 41
Optimizing high-frequency and low-frequency deep brain stimulation parameters for drug-resistant epilepsy: Mechanisms, clinical outcomes, and future directions
- 5 August 2025
- Published by Elsevier in Interdisciplinary Neurosurgery
- Vol. 41
Open AccessOptimizing high-frequency and low-frequency deep brain stimulation parameters for drug-resistant epilepsy: Mechanisms, clinical outcomes, and future directions
- Open Access
- 11 June 2025
- Published by AccScience Publishing in Advanced Neurology
- p. 8347
The role of high-density lipoprotein and Vitamin D in exercise-induced neuroprotection in epileptic rats
Previous studies have reported the neuroprotective effects of exercise in epilepsy. Hence, this study aimed to investigate the potential mechanisms underlying these neuroprotective effects by examining changes in high-density lipoprotein (HDL), low-density lipoprotein (LDL), and Vitamin D levels. Wistar rats were divided into four groups: sham, pentylenetetrazole (PTZ), exercise (EX), and PTZ + EX. Seizures were induced in the PTZ and PTZ + EX groups through intraperitoneal administration of PTZ (35 mg/kg) every other day for 1 month. The EX and PTZ + EX groups underwent daily exercise sessions (30 min/session) for 1 month. Serum levels of Vitamin D, HDL, and LDL were measured, and neuronal damage was assessed in the hippocampus and somatosensory cortex. The PTZ + EX group showed a significant increase in serum HDL and Vitamin D levels compared to the PTZ group. Histological analysis revealed a significant increase in neuronal damage in the PTZ group compared to the sham group. In contrast, both PTZ + EX and EX groups demonstrated a reduction in neuronal damage compared to the PTZ group. These findings suggest that HDL and Vitamin D may contribute to the neuroprotective benefits of exercise. Furthermore, exercise could potentially serve as a complementary strategy to counteract Vitamin D and HDL deficiencies associated with long-term antiepileptic drug use.
- 11 June 2025
- Published by AccScience Publishing in Advanced Neurology
- p. 8347
Open AccessThe role of high-density lipoprotein and Vitamin D in exercise-induced neuroprotection in epileptic rats
Previous studies have reported the neuroprotective effects of exercise in epilepsy. Hence, this study aimed to investigate the potential mechanisms underlying these neuroprotective effects by examining changes in high-density lipoprotein (HDL), low-density lipoprotein (LDL), and Vitamin D levels. Wistar rats were divided into four groups: sham, pentylenetetrazole (PTZ), exercise (EX), and PTZ + EX. Seizures were induced in the PTZ and PTZ + EX groups through intraperitoneal administration of PTZ (35 mg/kg) every other day for 1 month. The EX and PTZ + EX groups underwent daily exercise sessions (30 min/session) for 1 month. Serum levels of Vitamin D, HDL, and LDL were measured, and neuronal damage was assessed in the hippocampus and somatosensory cortex. The PTZ + EX group showed a significant increase in serum HDL and Vitamin D levels compared to the PTZ group. Histological analysis revealed a significant increase in neuronal damage in the PTZ group compared to the sham group. In contrast, both PTZ + EX and EX groups demonstrated a reduction in neuronal damage compared to the PTZ group. These findings suggest that HDL and Vitamin D may contribute to the neuroprotective benefits of exercise. Furthermore, exercise could potentially serve as a complementary strategy to counteract Vitamin D and HDL deficiencies associated with long-term antiepileptic drug use.
- 20 May 2025
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 75 (2) , 68
Interplay of Neuroinflammation and Epilepsy in Glioblastoma Multiforme: Mechanisms and Therapeutic Implications
Glioblastoma multiforme (GBM) is the most aggressive form of primary brain cancer in adults and is characterized by poor prognosis and a high incidence of seizures due to tumor-induced alterations in cerebral physiology. This review explores the complex interactions between GBM-induced neuroinflammation and epilepsy, emphasizing the mechanisms of epileptogenesis influenced by blood-brain barrier dysfunction, ion homeostasis, and neurotransmitter dynamics. We discuss the roles of pro-inflammatory mediators such as interleukin-1β and tumor necrosis factor-alpha in exacerbating excitatory synaptic activity while inhibiting inhibitory signaling, thus creating a milieu conducive to seizure activity. Furthermore, we evaluated the efficacy of current anti-seizure medications and emerging therapeutic strategies, including the reprogramming of tumor-associated macrophages, in managing GBM-related epilepsy and tumor growth. This study aimed to elucidate the critical pathways connecting GBM and epilepsy, thereby advancing our understanding of potential interventional approaches to improve patient outcomes.
- 20 May 2025
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 75 (2) , 68
Interplay of Neuroinflammation and Epilepsy in Glioblastoma Multiforme: Mechanisms and Therapeutic Implications
Glioblastoma multiforme (GBM) is the most aggressive form of primary brain cancer in adults and is characterized by poor prognosis and a high incidence of seizures due to tumor-induced alterations in cerebral physiology. This review explores the complex interactions between GBM-induced neuroinflammation and epilepsy, emphasizing the mechanisms of epileptogenesis influenced by blood-brain barrier dysfunction, ion homeostasis, and neurotransmitter dynamics. We discuss the roles of pro-inflammatory mediators such as interleukin-1β and tumor necrosis factor-alpha in exacerbating excitatory synaptic activity while inhibiting inhibitory signaling, thus creating a milieu conducive to seizure activity. Furthermore, we evaluated the efficacy of current anti-seizure medications and emerging therapeutic strategies, including the reprogramming of tumor-associated macrophages, in managing GBM-related epilepsy and tumor growth. This study aimed to elucidate the critical pathways connecting GBM and epilepsy, thereby advancing our understanding of potential interventional approaches to improve patient outcomes.
- 10 August 2023
- Published by Wiley in International Journal of Developmental Neuroscience
- Vol. 83 (8) , 677-690
The role of neurotransmitters in glioblastoma multiforme‐associated seizures
GBM, or glioblastoma multiforme, is a brain tumor that poses a great threat to both children and adults, being the primary cause of death related to brain tumors. GBM is often associated with epilepsy, which can be debilitating. Seizures and the development of epilepsy are the primary symptoms that have a severe impact on the quality of life for GBM patients. It is increasingly apparent that the nervous system plays an essential role in the tumor microenvironment for all cancer types, including GBM. In recent years, there has been a growing understanding of how neurotransmitters control the progression of gliomas. Evidence suggests that neurotransmitters and neuromodulators found in the tumor microenvironment play crucial roles in the excitability, proliferation, quiescence, and differentiation of neurons, glial cells, and neural stem cells. The involvement of neurotransmitters appears to play a significant role in various stages of GBM. In this review, the focus is on presenting updated knowledge and emerging ideas regarding the interplay between neurotransmitters and neuromodulators, such as glutamate, GABA, norepinephrine, dopamine, serotonin, adenosine, and their relationship with GBM and the seizures induced by this condition. The review aims to explore the current understanding and provide new insights into the complex interactions between these neurotransmitters and neuromodulators in the context of GBM‐related seizures.
- 10 August 2023
- Published by Wiley in International Journal of Developmental Neuroscience
- Vol. 83 (8) , 677-690
The role of neurotransmitters in glioblastoma multiforme‐associated seizures
GBM, or glioblastoma multiforme, is a brain tumor that poses a great threat to both children and adults, being the primary cause of death related to brain tumors. GBM is often associated with epilepsy, which can be debilitating. Seizures and the development of epilepsy are the primary symptoms that have a severe impact on the quality of life for GBM patients. It is increasingly apparent that the nervous system plays an essential role in the tumor microenvironment for all cancer types, including GBM. In recent years, there has been a growing understanding of how neurotransmitters control the progression of gliomas. Evidence suggests that neurotransmitters and neuromodulators found in the tumor microenvironment play crucial roles in the excitability, proliferation, quiescence, and differentiation of neurons, glial cells, and neural stem cells. The involvement of neurotransmitters appears to play a significant role in various stages of GBM. In this review, the focus is on presenting updated knowledge and emerging ideas regarding the interplay between neurotransmitters and neuromodulators, such as glutamate, GABA, norepinephrine, dopamine, serotonin, adenosine, and their relationship with GBM and the seizures induced by this condition. The review aims to explore the current understanding and provide new insights into the complex interactions between these neurotransmitters and neuromodulators in the context of GBM‐related seizures.
- Open Access
- 4 July 2023
- Published by Brieflands in Iranian Journal of Psychiatry and Behavioral Sciences
- Vol. 17 (2)
Daily Oral Memantine Attenuated the Severity of Borderline Personality Disorder Symptoms: A Double-Blind Placebo-Controlled, Randomized Clinical Trial
Background: Borderline personality disorder (BPD) has been considered a psychiatric disorder, the effective pharmacological treatments for which have not been well established. Objectives: This study aimed to assess the efficacy of memantine (10 mg/day) in reducing BPD severity and cognitive impairment. Methods: The BPD patients diagnosed by psychologists were included and divided into the placebo (n = 19) and memantine (n = 20) groups. Included participants were randomized, double-blinded, and stabilized on the medication and psychotherapy for at least four weeks. The patients in the memantine group received oral memantine (10 mg/day) for four weeks. The severity of BPD was assessed by a self-reported questionnaire named Borderline Evaluation of Severity Over Time (BEST). Moreover, the Wisconsin test was carried out to assess executive function. Results: The mean score of the BEST test significantly decreased in week eight post-treatment in the memantine group. In addition, a significant decrease in this score was indicated in the memantine group compared to the placebo group in week eight. The mean total score of the BEST test was not significantly different before and after the placebo administration. There was no significant difference in the Wisconsin subscales, including the number of wrong answers and categories achieved after memantine or placebo administration. Perseverative errors rose after the administration of memantine. Adverse side effects did not occur in any of the participants. Conclusions: Our findings suggested the potential therapeutic effects of memantine for BPD. Furthermore, we found that a low dose of meantime might be preferable to prevent the side effects.
- 4 July 2023
- Published by Brieflands in Iranian Journal of Psychiatry and Behavioral Sciences
- Vol. 17 (2)
Open AccessDaily Oral Memantine Attenuated the Severity of Borderline Personality Disorder Symptoms: A Double-Blind Placebo-Controlled, Randomized Clinical Trial
Background: Borderline personality disorder (BPD) has been considered a psychiatric disorder, the effective pharmacological treatments for which have not been well established. Objectives: This study aimed to assess the efficacy of memantine (10 mg/day) in reducing BPD severity and cognitive impairment. Methods: The BPD patients diagnosed by psychologists were included and divided into the placebo (n = 19) and memantine (n = 20) groups. Included participants were randomized, double-blinded, and stabilized on the medication and psychotherapy for at least four weeks. The patients in the memantine group received oral memantine (10 mg/day) for four weeks. The severity of BPD was assessed by a self-reported questionnaire named Borderline Evaluation of Severity Over Time (BEST). Moreover, the Wisconsin test was carried out to assess executive function. Results: The mean score of the BEST test significantly decreased in week eight post-treatment in the memantine group. In addition, a significant decrease in this score was indicated in the memantine group compared to the placebo group in week eight. The mean total score of the BEST test was not significantly different before and after the placebo administration. There was no significant difference in the Wisconsin subscales, including the number of wrong answers and categories achieved after memantine or placebo administration. Perseverative errors rose after the administration of memantine. Adverse side effects did not occur in any of the participants. Conclusions: Our findings suggested the potential therapeutic effects of memantine for BPD. Furthermore, we found that a low dose of meantime might be preferable to prevent the side effects.
- Open Access
- 20 March 2023
- Published by Academic World Research in Medical Journal of the Islamic Republic Of Iran
- Vol. 37 (1) , 324-331
High and Low-Frequency Stimulation Effect on Epileptiform Activity in Brain Slices
Background: Neurostimulation is one of the new therapeutic approaches in patients with drug-resistant epilepsy, and despite its high efficiency, its mechanism of action is still unclear. On the one hand, electrical stimulation in the human brain is immoral; on the other hand, the creation of the epilepsy model in laboratory ...
- 20 March 2023
- Published by Academic World Research in Medical Journal of the Islamic Republic Of Iran
- Vol. 37 (1) , 324-331
Open AccessHigh and Low-Frequency Stimulation Effect on Epileptiform Activity in Brain Slices
Background: Neurostimulation is one of the new therapeutic approaches in patients with drug-resistant epilepsy, and despite its high efficiency, its mechanism of action is still unclear. On the one hand, electrical stimulation in the human brain is immoral; on the other hand, the creation of the epilepsy model in laboratory ...